J.P. Morgan is out with its report today on Vertex Pharmaceuticals VRTX, raising its PT from $46 to $53.
In a note to clients, J.P. Morgan writes, "Overall, we view Incivek pricing as an upside surprise but one that was widely anticipated by the market, and, at the end of the day, the Vertex story will likely soon shift to IMS data/actual sales/share, not clinical data interpretation. Based on the pricing, we're raising our 2011 and 2012 US sales assumptions by $82M (to $592M) and $255M (to $1.79B), respectively, which drives our PT to $53 from $46. Maintain Neutral."
Shares of VRTX closed Monday at $55.81, up 1.47% from Friday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsBiotechnologyHealth CareJ.P. Morganvertex pharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in